Welcome to the international HTA database

Showing [25206 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Diagnostics of endometriosis]
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Methods, ways of working, and efforts to prevent recidivism for perpetrators of domestic or honor-based violence]
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Home based health care: enablers and barriers to quality of care and patient safety]
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Diagnostic accuracy of different index tests in diagnosing suspected peanut allergy]
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Organisational and social work environment and mental ill-health]
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[The dental care system’s opportunities to prevent and identify medical diagnoses and health conditions]
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[A map of systematic reviews that have examined how sexual risk exposure can be identified or how mental illness among sexually exposed individuals can be treated]
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Interventions aimed at increasing physical activity in people with intellectual disabilities or autism spectrum disorder]
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Extended postnatal home visiting programs]
2027	Norwegian Medical Products Agency (NOMA)	[PIK3CA, PIK3R1, and PTEN alteration testing in colorectal cancer surgery patients to evaluate adjuvant acetylsalicylic acid treatment]
2027	Health Information and Quality Authority (HIQA)	Health Technology Assessment (HTA) of the transition to, and coordination of, adult healthcare services for individuals with severe neurological impairment
2027	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Anxiety and panic disorder: do those affected benefit from the "emotional freedom technique”?]
2027	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Short frenulum in infants: what are the advantages and disadvantages of frenectomy (cutting the frenulum) compared to, for example, breastfeeding counseling for breastfeeding problems?]
2027	Norwegian Medical Products Agency (NOMA)	[Wearable cardioverter defibrillator (LifeVest) for people with high risk of sudden cardiac arrest: a single technology assessment]
2027	Belgian Health Care Knowledge Centre (KCE)	Review of new oncology indications for the use of positron emission tomography (PET-scans) (Study 2024-12)
2026	Ontario Health	Renal denervation for uncontrolled hypertension
2026	Ontario Health	Hepatitis C screening
2026	Ontario Health	Ablative technologies for thyroid nodules
2026	Ontario Health	Preimplantation genetic testing for aneuploidy, monogenic disorders and structural rearrangements
2026	Center for Outcomes Research and Economic Evaluation for Health (C2H)	Cost-effectiveness evaluation of Nirmatrelvir/Ritonavir (Paxlovid)
2026	NIHR Health Technology Assessment programme	Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation
2026	NIHR Health Technology Assessment programme	Ethical implications of the use of AI-based technologies for medical image classification systems in screening: a qualitative systematic review
2026	National Institute for Health and Care Excellence (NICE)	Sotatercept for treating pulmonary arterial hypertension. NICE technology appraisal guidance 1161
2026	National Institute for Health and Care Excellence (NICE)	Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 1160
2026	National Institute for Health and Care Excellence (NICE)	Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment. NICE technology appraisal guidance 1159
2026	National Institute for Health and Care Excellence (NICE)	Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation). NICE technology appraisal guidance 1163
2026	National Institute for Health and Care Excellence (NICE)	Nusinersen and risdiplam for treating spinal muscular atrophy. NICE technology appraisal guidance 1162
2026	National Institute for Health and Care Excellence (NICE)	Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment. NICE technology appraisal guidance 1164
2026	National Institute for Health and Care Excellence (NICE)	Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer. NICE technology appraisal guidance 1165
2026	National Institute for Health and Care Excellence (NICE)	Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils. NICE technology appraisal guidance 1166
2026	National Institute for Health and Care Excellence (NICE)	Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation). NICE technology appraisal guidance 1168
2026	National Institute for Health and Care Excellence (NICE)	Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 1167
2026	National Institute for Health and Care Excellence (NICE)	Seladelpar for previously treated primary biliary cholangitis. NICE technology appraisal guidance 1171
2026	National Institute for Health and Care Excellence (NICE)	Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable. NICE technology appraisal guidance 1170
2026	National Institute for Health and Care Excellence (NICE)	Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 1169
2026	National Institute for Health and Care Excellence (NICE)	Atogepant for treating migraine. NICE technology appraisal guidance 1172
2026	NIHR Health Technology Assessment programme	Plain balloon angioplasty +/- bare metal stenting versus drug-coated balloon angioplasty +/- bare metal stenting versus primary drug-eluting stenting in patients with chronic limb-threatening ischaemia: BASIL-3, an open-label, three-arm, randomised, multi-centre, phase 3 trial
2026	NIHR Health Technology Assessment programme	Effectiveness of psychosocial interventions for adults with substance use disorder that have a co-occurring mental health disorder: an umbrella review and illustrative cost-effectiveness analysis
2026	NIHR Health Services and Delivery Research programme	A realist synthesis of integrated palliative care and oncology: synopsis
2026	NIHR Health Technology Assessment programme	Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial
2026	NIHR Health Technology Assessment programme	Placental growth factor (PLGF)-based testing to help diagnose suspected pre-eclampsia: a systematic review and economic evaluation
2026	NIHR Health Technology Assessment programme	Digital front door technologies to pre-assess people before assessment for NHS Talking Therapies [HTE10055]: early value assessment
2026	NIHR Health Technology Assessment programme	Effectiveness of non-pharmacological interventions for fatigue in adults with long-term conditions: a synopsis of the EIFFEL mixed-methods evidence synthesis
2026	NIHR Health Services and Delivery Research programme	Family Group Conferences as an alternative to Initial Child Protection Conferences for families on the Child Protection pathway: synopsis
2026	Health Technology Wales (HTW)	Cone-beam computed tomography for breast imaging in people with suspected breast cancer
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Diagnostic accuracy of different index-tests in diagnosing food allergy]
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Assessment tools for identifying individuals exposed to prostitution, human trafficking for sexual purposes, and sexual exploitation through the dissemination of images or videos]
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[The role of occupational exposures in the development of cancer among firefighters]
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Newborn screening of mucopolysaccharidosis type 1]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Digital self-care solutions for chronic insomnia]
2026	NIHR Health Technology Assessment programme	Newborn screening for severe combined immunodeficiency in the NHS newborn blood spot screening programme: a systematic review
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[National plan for better addiction treatment]
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Prioritisation of knowledge needs concerning home care for older adults]
2026	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Suvanto Care Safety Service
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[The relevance of hearing screening for workers in the Quebec context]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Digital self-care solutions for diabetes]
2026	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[An evaluation of the safety, efficacy, clinical effectiveness, efficiency and organisational aspects of the implementation of model-based dosing systems for the treatment of inflammatory bowel disease]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Pharmacological treatment – anxiety disorder or obsessive-compulsive disorder in young people aged 12 to 17]
2026	NIHR Health Technology Assessment programme	PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine data
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Antibiotic prophylaxis for gynecological and obstetrical surgeries and procedures]
2026	Norwegian Medical Products Agency (NOMA)	[Repetitive transcranial magnetic stimulation for treatment-resistant moderate and severe depression: a health technology assessment]
2026	Norwegian Medical Products Agency (NOMA)	[Blood-based biomarker tests for Alzheimer's disease: a mapping review]
2026	NIHR Health Services and Delivery Research programme	Attracting, recruiting, and retaining registered nurses and care workers in care homes: the REACH realist review
2026	NIHR Health Technology Assessment programme	Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model
2026	NIHR Health Services and Delivery Research programme	Pressure Ulcer Prevention at Home for People with Long-term Neurological Conditions, Carers and Personal Assistants: synopsis – a participatory, qualitative study (PUP@Home1)
2026	NIHR Health Services and Delivery Research programme	Recovery Colleges for post-diagnostic dementia support: the DiSCOVERY realist evaluation synopsis
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Effectiveness and safety of robotic surgery: rectal and colon cancers, benign and malignant pancreatic tumours, and obesity]
2026	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of Sacituzumab Govitecan (TRODELVY)]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Effectiveness and safety of robotic surgery: total hysterectomy for endometrial cancer, radical prostatectomy for prostate cancer, and partial nephrectomy for renal cancer]
2026	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of Teprotumumab (TEPEZZA)]
2026	NIHR Health Technology Assessment programme	Prevention and treatment of incontinence-associated dermatitis through optimising care: the PREVENT-IAD Synopsis
2026	NIHR Health Services and Delivery Research programme	Developing the evidence and associated service models to improve pain management in older people living with frailty: a synopsis of the POPPY mixed method, co-design study
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Robotic surgery – relevance and optimal framework for three oncological indications: total hysterectomy for endometrial cancer, radical prostatectomy for prostate cancer, and partial nephrectomy for renal cancer]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Relevance of intraperitoneal chemotherapy for preventing or treating neoplasms of the peritoneal surfaces - peritoneal metastases secondary to colorectal cancer]
2026	Andalusian Health Technology Assessment Area (AETSA)	[Assessment of body composition and muscular functionality in the oncology patient. Systematic review]
2026	National Institute for Health and Care Excellence (NICE)	Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment. NICE HealthTech guidance 779
2026	National Institute for Health and Care Excellence (NICE)	Digital technologies to support self-management of asthma: early-use assessment. NICE HealthTech guidance 778
2026	National Institute for Health and Care Excellence (NICE)	Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal). NICE technology appraisal guidance 1151
2026	National Institute for Health and Care Excellence (NICE)	Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1150
2026	National Institute for Health and Care Excellence (NICE)	Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal). NICE technology appraisal guidance 1154
2026	National Institute for Health and Care Excellence (NICE)	Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment. NICE technology appraisal guidance 1153
2026	National Institute for Health and Care Excellence (NICE)	Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity. NICE technology appraisal guidance 1152
2026	National Institute for Health and Care Excellence (NICE)	Rozanolixizumab for treating antibody-positive generalised myasthenia gravis. NICE technology appraisal guidance 1155
2026	National Institute for Health and Care Excellence (NICE)	Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy. NICE technology appraisal guidance 1156
2026	National Institute for Health and Care Excellence (NICE)	Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1158
2026	National Institute for Health and Care Excellence (NICE)	Givinostat for treating Duchenne muscular dystrophy in people 6 years and over. NICE technology appraisal guidance 1157
2026	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Virtual reality for the treatment of chronic pain]
2026	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Neuromodulator medical device for the treatment of opioid use disorder]
2026	Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII)	[Evaluation of injectable type I collagen in AMIC/ACIC arthroscopic applications]
2026	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Early treatment response prognostic marker based on the elimination of blast cells in peripheral blood in acute myeloid leukemia]
2026	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Treatment of amblyopia in the pediatric population through dichoptic therapy]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Appropriate use of laboratory tests – erythrocyte sedimentation rate test]
2026	NIHR Health Services and Delivery Research programme	Accounting for unmet need in equitable healthcare resource allocation: synopsis
2026	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Mass spectrometry from blood samples for the detection of minimal residual disease in patients with multiple myeloma]
2026	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Personalised treatment protocol with rituximab based on artificial intelligence in membranous nephropathy]
2026	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Early treatment response prediction marker based on the clearance of blast cells in peripheral blood in acute myeloid leukaemia]
2026	NIHR Health Technology Assessment programme	Developing a national triage tool for use in NHS regional trauma networks: the MATTS mixed methods study
2026	NIHR Health Services and Delivery Research programme	Evaluating the national rollout of the NHS App in England using qualitative and quantitative methods
2026	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Immunological panel for the evaluation of T cell responses to cytomegalovirus antigens in lung transplant recipients]
2026	Health Information and Quality Authority (HIQA)	A scoping review of publicly-funded services for donor-assisted human reproduction in selected countries